# EDGAR Filing Document

**Accession Number:** 0000926617
**File Stem:** 0000926617-23-000011
**Filing Date:** 2023-2
**Character Count:** 9357
**Document Hash:** 8b2a7ede305a710a98b6547f2a5254f4
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000926617-23-000011.hdr.sgml**: 20230207

**ACCESSION NUMBER**: 0000926617-23-000011

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20230206

**ITEM INFORMATION**: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230207

**DATE AS OF CHANGE**: 20230207

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Aspira Women's Health Inc.
- **CENTRAL INDEX KEY:** 0000926617
- **STANDARD INDUSTRIAL CLASSIFICATION:** IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
- **IRS NUMBER:** 330595156
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-34810
- **FILM NUMBER:** 23594988

**BUSINESS ADDRESS:**
- **STREET 1:** 12117 BEE CAVES ROAD BUILDING THREE
- **STREET 2:** SUITE 100
- **CITY:** AUSTIN
- **STATE:** TX
- **ZIP:** 78738
- **BUSINESS PHONE:** 512-519-0400

**MAIL ADDRESS:**
- **STREET 1:** 12117 BEE CAVES ROAD BUILDING THREE
- **STREET 2:** SUITE 100
- **CITY:** AUSTIN
- **STATE:** TX
- **ZIP:** 78738

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** VERMILLION, INC.
- **DATE OF NAME CHANGE:** 20070824

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CIPHERGEN BIOSYSTEMS INC
- **DATE OF NAME CHANGE:** 20000316

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ABIOTIC SYSTEMS
- **DATE OF NAME CHANGE:** 19950407

?xml version="1.0" encoding="utf-8"? awh-20230206x8k

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**Form 8-K** 

**CURRENT REPORT** 

**Pursuant to Section 13 or 15(d) of** 

**the Securities Exchange Act of 1934** 

**Date of Report (Date of earliest event reported): February 6, 2023**

**Aspira Women's Health Inc.** 

**(Exact name of registrant as specified in its charter)** 

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-34810** | **33-0595156** |
| (State or other jurisdiction<br>‎of incorporation) | (Commission<br>‎File Number) | (IRS Employer<br>‎Identification No.) |

---

---

| | |
|:---|:---|
| **12117 Bee Caves Road, Building III, Suite 100, Austin, Texas** | **78738** |
| (Address of principal executive offices) | (Zip Code) |

---

**Registrant's telephone number, including area code: (512) 519-0400** 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| <u>Title of each class</u> | <u>Trading Symbol(s)</u> | <u>Name of each exchange on which registered</u> |
| Common Stock, par value $0.001 per share | AWH | Nasdaq Capital Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ◻

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

------

### **Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.** 

### On February 6, 2023, Aspira Women's Health Inc. (the "Company") filed with the Secretary of State of the State of Delaware a Certificate of Amendment to the Company's Fourth Amended and Restated Certificate of Incorporation, as amended, to increase the authorized number of shares of the Company's common stock from 150,000,000 shares to 200,000,000 shares, and accordingly to increase the total number of shares that the Company is authorized to issue to 205,000,000. A complete copy of the Company's Amended and Restated Certificate of Incorporation, as amended to date, is attached hereto as Exhibit 3.1.

### **Item 5.07. Submission of Matters to a Vote of Security Holders.** 

### On February 6, 2023, the Company held a special meeting of stockholders (the "Special Meeting"). As of the close of business on the record date for the Special Meeting, there were 124,594,888 shares of the Company's common stock, par value $0.001 per share, issued and outstanding and entitled to vote. There were 94,661,807 shares present in person or by proxy at the Special Meeting, constituting a quorum. At the Special Meeting, the Company's stockholders voted on one proposal, which is described in more detail in the Company's definitive proxy statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on December 28, 2022. The following is a brief description of the sole matter voted upon and the results, including the number of votes cast for and against each matter as well as the number of abstentions and broker non-votes with respect to such matter.

### <u>Proposal 1: Increase in Authorized Shares</u> 
The Company's stockholders approved an amendment to the Company's Fourth Amended and Restated Certificate of Incorporation, as amended, to increase the number of authorized shares of the Company's common stock from 150,000,000 shares to 200,000,000 shares, and accordingly to increase the total number of shares that the Company is authorized to issue to 205,000,000. The final voting results were as follows:

---

| | | | |
|:---|:---|:---|:---|
| **<u>FOR</u>** | **<u>AGAINST</u>** | **<u>ABSTENTIONS</u>** | **<u>BROKER NON-VOTES</u>** |
| 93,255,545 | 1,238,679 | 167,583 | 0 |

---

## Item 9.01. Financial Statements and Exhibits
(d) *Exhibits.*

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| [<u>3.1</u>](awh-20230206xex3_1.htm) | [<u>Certificate of Amendment to the Fourth Amended and Restated Certificate of Incorporation, as amended.</u>](awh-20230206xex3_1.htm) |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ASPIRA WOMEN'S HEALTH INC.**

Date: February 7, 2023By: <u>/s/ Marlene McLennan</u> 

Marlene McLennan

Interim Chief Financial Officer

## Exhibit 3.1

**Exhibit 3.1**

**CERTIFICATE OF AMENDMENT TO THE**

**FOURTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF**

**ASPIRA WOMEN'S HEALTH INC.**

Aspira Women's Health Inc. (the "<u>Corporation</u>"), a corporation duly organized and existing under and by virtue of the General Corporation Law of the State of Delaware, hereby certifies as follows:

&nbsp;&nbsp;&nbsp;&nbsp;1. This Certificate of Amendment amends the provisions of the Corporation's Fourth Amended and Restated Certificate of Incorporation filed with the Secretary of State of the State of Delaware on January 22, 2010, as amended by the Certificate of Amendment filed with the Secretary of State of the State of Delaware on June 27, 2014 and further amended by the Certificate of Amendment filed with the Secretary of State of the State of Delaware on June 11, 2020 (the " <u>Certificate of Incorporation</u> ").

------

&nbsp;&nbsp;&nbsp;&nbsp;2. The board of directors of the Corporation, acting in accordance with the provisions of Sections 141 and 242 of the General Corporation Law of the State of Delaware, adopted resolutions amending the first paragraph of A rticle IV of the Certificate of Incorporation, as amended, to read as follows :

"The corporation is authorized to issue two classes of shares of stock to be designated, respectively, Common Stock, $0.001 par value, and Preferred Stock, $0.001 par value. The total number of shares that the corporation is authorized to issue is 205,000,000 shares. The number of shares of Common Stock authorized is 200,000,000. The number of shares of Preferred Stock authorized is 5,000,000."

&nbsp;&nbsp;&nbsp;&nbsp;3. This Certificate of Amendment to the Fourth Amended and Restated Certificate of Incorporation was submitted to the stockholders of the Company and was duly adopted and approved in accordance with the provisions of Section 242 of the General Corporate Law of the State of Delaware at a special meeting of the stockholders of the Company.

IN WITNESS WHEREOF, the Corporation has caused this Certificate of Amendment to be executed by its duly authorized officer on this 6<sup>th</sup> day of February 2023.

---

| | |
|:---|:---|
| &nbsp;&nbsp; **Aspira Women's Health Inc.** | &nbsp;&nbsp; **Aspira Women's Health Inc.** |
| &nbsp;&nbsp; By: | &nbsp;&nbsp; /s/ Nicole Sandford |
| &nbsp;&nbsp; Nicole Sandford <br> President and Chief Executive Officer | &nbsp;&nbsp; Nicole Sandford <br> President and Chief Executive Officer |

---

------